FINWIRES · TerminalLIVE
FINWIRES

Fiserv Sees Double-Digit EPS Growth Returning as It Expands Agentic AI Push, RBC Says

By

Fiserv (FISV) is positioning itself for a return to double-digit adjusted earnings growth while expanding its push into agentic AI and banking automation through its new AgentOS platform, RBC Capital Markets said.

The investment firm said in a Thursday research note that AgentOS is designed to create AI agents that operate across banking workflows within regulated environments.

Fiserv is collaborating with OpenAI and Amazon (AMZN) Bedrock AgentCore on the platform, with six financial institutions already participating in development efforts and two running agents in beta, RBC said.

The firm also highlighted continued momentum in Merchant Solutions, where Clover represented about $3.3 billion in revenue in 2025.

RBC said the company is focused on improving Core migration dynamics and reducing attrition through investments in service-level improvements and a more modular migration approach.

RBC has an outperform rating with a $75 price target on Fiserv.

Shares of the company were up 1.8% in Friday afternoon trading.

Price: $54.44, Change: $+0.98, Percent Change: +1.83%

Related Articles

Australia

Repligen Likely to Benefit From Diverse Growth Factors, RBC Says

Repligen (RGEN) is expected to benefit from diverse growth drivers in a strengthening bioprocessing market, RBC Capital Markets said in a Thursday note."Bioprocessing demand trends are the most robust in Tools, and Repligen is a pure play," the note said.The report also pointed to growth prospects at its commercial products, biosimilars, product replacement cycles, and a strategyreboot in China.The note said the growth drivers should enable the firm to return to mid-teens organic sales growth, as RBC resumes coverage of Repligen with an outperform rating and a $160 price target."The growth pressures associated with a specific gene therapy customer should lap next year, while several tailwinds...should ramp," the report said.Price: $105.97, Change: $+2.59, Percent Change: +2.50%

$RGEN
Australia

Update: Federal Reserve Terminates Enforcement Actions With UBS, Credit Suisse

(Updates with UBS' response to a request for comment.)The Federal Reserve said Friday it has terminated its enforcement actions with UBS Group (UBS), Credit Suisse and their subsidiaries.UBS declined to comment to.Price: $45.46, Change: $-0.89, Percent Change: -1.92%

$UBS
Australia

Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says

Illumina's (ILMN) mid-teens clinical growth appears sustainable over the next one to two years, driven largely by oncology testing and screening applications, as the company sees building clinical momentum and fading competitive concerns, RBC said in a Thursday note.With clinical markets now comprising over 50% of the company's sales, growth has accelerated to 20% in each of the past two quarters, supported by robust growth forecasts for Illumina's oncology customers, according to the note.Illumina sees fading competitive concerns with Roche's Axelios 1 sequencing update seeing mixed response, RBC said, adding that it did not see any updates at Roche's investor event earlier this week to change the narrative.Additionally, RBC said that the weakness Illumina is seeing in academic demand is an industry-wide problem and that several new product launches should enable demand to at least flatten by next year, which will be enough to meet or exceed Wall Street forecasts.RBC has an outperform rating on the company, with a $170 price target.Price: $139.93, Change: $-3.31, Percent Change: -2.31%

$ILMN